Geoff Pardo joined Gilde Healthcare in 2011 as a Partner working out of the office in Boston/Cambridge, MA and is focusing on Gilde’s investments in North America. He led the investments in Inari Medical (NASDAQ: NARI), Axonics Modulation Technologies (NASDAQ: AXNX), Eargo (NASDAQ: EAR), CVRx, Ablative Solutions, Vesper Medical, InovaLabs (acquired by ResMed), BionX (acquired by Ottobock) and Vapotherm (NYSE: VAPO) and represents or has represented Gilde as a member of the board of directors for each company. Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience (sold to J&J) and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics. Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. He has also worked at Cardinal Partners as an Associate leading their investing activity in the medical device sector. Geoff began his career in medical devices as a product manager with Synthes USA, and he has a BA with honors in History from Brown University and an MBA from the Wharton School of Business. He is a US citizen based in Gilde Healthcare’s Cambridge, MA office.
Swaril Mathur is a strategic growth leader with deep expertise in building and scaling transformative medical technologies through early-stage innovation, M&A, and go-to-market execution. Most recently, as Vice President of Business Development at Axonics, she led M&A and strategic initiatives, including the company’s $3.7B acquisition by Boston Scientific. Prior to joining Axonics, Swaril drove early-stage innovation at Edwards Lifesciences as a member of the Advanced Technology group, and at Stanford University as a Biodesign Innovation Fellow. In these roles, she partnered with engineers and physicians to identify and address unmet clinical needs in cardiology and otolaryngology. She remains actively involved with Stanford Biodesign, currently co-teaching its Global Faculty Training program, which equips international leaders to support needs-driven healthcare innovation in their home countries. Swaril began her career at Boston Consulting Group, supporting strategic transformations and business integrations for leading healthcare clients. She holds an M.S. in Bioengineering from Stanford University and a B.S. in Biomedical Engineering from the University of California, Irvine.
Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate Biosciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular (acquired), Metavention, Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Plexium, Relievant Medsystems (acquired), Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired). Justin currently serves as a member of the Board of Directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Chair of its MedTech Investment Working Group. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.
